Skip to main content
Erschienen in: Clinical Pharmacokinetics 4/2008

01.04.2008 | Review Article

Facilitation of Drug Evaluation in Children by Population Methods and Modelling

verfasst von: Dr Michel Tod, Vincent Jullien, Gérard Pons

Erschienen in: Clinical Pharmacokinetics | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

The pharmacokinetics and pharmacodynamics of drugs are different in adult and paediatric populations, the latter being particularly heterogeneous. These differences in pharmacokinetics and pharmacodynamics justify specific studies but raise a number of ethical and practical issues. The main practical difficulties to circumvent while performing clinical studies in children are the invasiveness of the procedures and the obstacles to patient recruitment. The invasiveness related to pain/anxiety and blood loss precludes the performance of classical pharmacokinetic studies in children in many instances, particularly in neonates and infants. Population approaches, which rely on pharmacokinetic-pharmacodynamic modelling, are particularly appealing in paediatric populations because these models can cope with sparse data. The relevance of population approaches to investigation of the dose-concentration-effect relationships and to qualitative/quantitative assessment of factors that may explain interindividual variability has already been emphasized.
The aims of this review are to summarize the currently available literature on population pharmacokineticpharmacodynamic studies in children and to discuss a number of recent methodological developments that may facilitate the evaluation of drugs in this population by alleviating invasiveness and, subsequently, facilitating recruitment of patients. The present survey confirms that population approaches in paediatrics have already reached a large audience and that they are mostly used for analysis of sparse data. However, pharmacokineticpharmacodynamic studies in children are still scarce. New classes of models may extend the scope of the use of population models in paediatrics. Kinetic-pharmacodynamic models, where use of the term ‘kinetic’ rather than ‘pharmacokinetic’ emphasizes the absence of pharmacokinetic data, are indirect models where the (unobserved) drug kinetics are described by a single compartment involving a single rate constant. These models, which alleviate the need for blood samples used for the measurement of drug concentration, may be very useful in paediatric studies. Physiological and physiopathological models also have potential applications but require further development. Because the number of measurements in a single individual needs to be limited in children, it is crucial to optimize the design of the experiment in order to avoid inaccurate and unreliable results. In this review, formal optimization and simulation to evaluate a design are presented, and specific problems raised by the application of these techniques in paediatrics are addressed. Finally, the related technique of clinical trial simulation and its applications are presented and discussed.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
2.
Zurück zum Zitat Rosato J. The ethics of clinical trials: a child’s view. J Law Med Ethics 2000; 28: 362–78PubMedCrossRef Rosato J. The ethics of clinical trials: a child’s view. J Law Med Ethics 2000; 28: 362–78PubMedCrossRef
3.
Zurück zum Zitat American Academy of Pediatrics Committee on Drugs. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995; 95: 286–94 American Academy of Pediatrics Committee on Drugs. Guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations. Pediatrics 1995; 95: 286–94
4.
Zurück zum Zitat Jong GW, Vuto AG, de Hoog M, et al. Unapproved and off-label use of drugs in a children’s hospital [letter]. N Engl J Med 2000; 343: 1125PubMedCrossRef Jong GW, Vuto AG, de Hoog M, et al. Unapproved and off-label use of drugs in a children’s hospital [letter]. N Engl J Med 2000; 343: 1125PubMedCrossRef
5.
Zurück zum Zitat Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000; 320: 79–82PubMedCrossRef Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. BMJ 2000; 320: 79–82PubMedCrossRef
6.
Zurück zum Zitat Treluyer JM, Berger JF, Leclerc F, et al. Use of off-label and unlicensed drugs in neonatal and paediatric intensive care in France [abstract no. 46A]. Pediatric Academic Societies Annual Meeting; 1999 May 1–4; San Francisco (CA) Treluyer JM, Berger JF, Leclerc F, et al. Use of off-label and unlicensed drugs in neonatal and paediatric intensive care in France [abstract no. 46A]. Pediatric Academic Societies Annual Meeting; 1999 May 1–4; San Francisco (CA)
7.
Zurück zum Zitat Bücheier R, Schwab M, Mörike K, et al. Offlabel prescribing to children in primary care in Germany: retrospective cohort study. BMJ 2002; 324: 1311–2CrossRef Bücheier R, Schwab M, Mörike K, et al. Offlabel prescribing to children in primary care in Germany: retrospective cohort study. BMJ 2002; 324: 1311–2CrossRef
8.
Zurück zum Zitat Schirm E, Tobi H, de Jong-van den Berg LT. Unlicensed and off label drug use by children in the community: cross sectional study. BMJ 2002; 324: 1312–3PubMedCrossRef Schirm E, Tobi H, de Jong-van den Berg LT. Unlicensed and off label drug use by children in the community: cross sectional study. BMJ 2002; 324: 1312–3PubMedCrossRef
9.
Zurück zum Zitat Jong GW, Eland IA, Sturkenboom MCJM, et al. Unlicensed and off-label prescription of drugs to children: population based cohort study. BMJ 2002; 324: 1313–4CrossRef Jong GW, Eland IA, Sturkenboom MCJM, et al. Unlicensed and off-label prescription of drugs to children: population based cohort study. BMJ 2002; 324: 1313–4CrossRef
10.
Zurück zum Zitat Chalumeau M, Treluyer JM, Salenave B, et al. Off label and unlicensed drug use among office-based paediatricians. Arch Dis Child 2000; 82: 502–5CrossRef Chalumeau M, Treluyer JM, Salenave B, et al. Off label and unlicensed drug use among office-based paediatricians. Arch Dis Child 2000; 82: 502–5CrossRef
11.
Zurück zum Zitat O’Donnell CPF, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002; 110: e52PubMedCrossRef O’Donnell CPF, Stone RJ, Morley CJ. Unlicensed and off-label drug use in an Australian neonatal intensive care unit. Pediatrics 2002; 110: e52PubMedCrossRef
12.
Zurück zum Zitat Nahata MC. Lack of pediatrie drug formulations. Pediatrics 1999; 104 Suppl.: 607–9PubMed Nahata MC. Lack of pediatrie drug formulations. Pediatrics 1999; 104 Suppl.: 607–9PubMed
13.
Zurück zum Zitat Kearns GL, Abdel-Rahman S, Alander SW, et al. Developmental pharmacologydrug disposition, action, and therapy in infants and children. N Eng J Med 2003; 349: 1157–67CrossRef Kearns GL, Abdel-Rahman S, Alander SW, et al. Developmental pharmacologydrug disposition, action, and therapy in infants and children. N Eng J Med 2003; 349: 1157–67CrossRef
15.
Zurück zum Zitat Gao Y, Pons G, Rey E, et al. Could saliva stand for plasma in theophylline monitoring in asthmatic children? Still a controversial problem. Fundam Clin Pharmacol 1992; 6(4–5): 191–6PubMedCrossRef Gao Y, Pons G, Rey E, et al. Could saliva stand for plasma in theophylline monitoring in asthmatic children? Still a controversial problem. Fundam Clin Pharmacol 1992; 6(4–5): 191–6PubMedCrossRef
16.
Zurück zum Zitat Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165(11): 741–6PubMedCrossRef Anderson BJ, Allegaert K, Holford NH. Population clinical pharmacology of children: general principles. Eur J Pediatr 2006; 165(11): 741–6PubMedCrossRef
17.
Zurück zum Zitat Meibohm B, Läer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7(2): E475–87PubMedCrossRef Meibohm B, Läer S, Panetta JC, et al. Population pharmacokinetic studies in pediatrics: issues in design and analysis. AAPS J 2005; 7(2): E475–87PubMedCrossRef
18.
Zurück zum Zitat Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30(2): 81–93PubMedCrossRef Vozeh S, Steimer JL, Rowland M, et al. The use of population pharmacokinetics in drug development. Clin Pharmacokinet 1996; 30(2): 81–93PubMedCrossRef
19.
Zurück zum Zitat Samara E, Granneman R. Role of population pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet 1997; 32(4): 294–312PubMedCrossRef Samara E, Granneman R. Role of population pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet 1997; 32(4): 294–312PubMedCrossRef
20.
Zurück zum Zitat Jackson KA, Rosenbaum SE. The application of population pharmacokinetics to the drug development process. Drug Dev Ind Pharm 1998; 24(12): 1155–62PubMedCrossRef Jackson KA, Rosenbaum SE. The application of population pharmacokinetics to the drug development process. Drug Dev Ind Pharm 1998; 24(12): 1155–62PubMedCrossRef
21.
Zurück zum Zitat Sun H, Fadiran EO, Jones CD, et al. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 1999; 37(1): 41–58PubMedCrossRef Sun H, Fadiran EO, Jones CD, et al. Population pharmacokinetics: a regulatory perspective. Clin Pharmacokinet 1999; 37(1): 41–58PubMedCrossRef
22.
Zurück zum Zitat Sheiner L, Wakefield J. Population modelling in drug development. Stat Methods Med Res 1999; 8(3): 183–93PubMedCrossRef Sheiner L, Wakefield J. Population modelling in drug development. Stat Methods Med Res 1999; 8(3): 183–93PubMedCrossRef
24.
Zurück zum Zitat Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989; 46(1): 63–77PubMedCrossRef Sheiner LB, Beal SL, Sambol NC. Study designs for dose-ranging. Clin Pharmacol Ther 1989; 46(1): 63–77PubMedCrossRef
25.
Zurück zum Zitat Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46(3): 221–34PubMedCrossRef Brendel K, Dartois C, Comets E, et al. Are population pharmacokinetic and/or pharmacodynamic models adequately evaluated? A survey of the literature from 2002 to 2004. Clin Pharmacokinet 2007; 46(3): 221–34PubMedCrossRef
30.
Zurück zum Zitat Läer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005; 46(7): 1322–30PubMedCrossRef Läer S, Elshoff JP, Meibohm B, et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005; 46(7): 1322–30PubMedCrossRef
31.
Zurück zum Zitat Uehlinger DE, Ding RW, Schärer K. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76–89PubMedCrossRef Uehlinger DE, Ding RW, Schärer K. A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 1992; 51: 76–89PubMedCrossRef
32.
Zurück zum Zitat Port RE, Ding RW, Fies T, et al. Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia. Br J Clin Pharmacol 1998; 46(5): 461–6PubMedCrossRef Port RE, Ding RW, Fies T, et al. Predicting the time course of haemoglobin in children treated with erythropoietin for renal anaemia. Br J Clin Pharmacol 1998; 46(5): 461–6PubMedCrossRef
33.
Zurück zum Zitat Jacqmin P, Snoeck E, van Schaick EA, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 2007; 34(1): 57–85PubMedCrossRef Jacqmin P, Snoeck E, van Schaick EA, et al. Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model. J Pharmacokinet Pharmacodyn 2007; 34(1): 57–85PubMedCrossRef
34.
Zurück zum Zitat Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004; 45(10): 3435–41PubMedCrossRef Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone acetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2004; 45(10): 3435–41PubMedCrossRef
35.
Zurück zum Zitat Pillai G, Gieschke R, Goggin T, et al. A semimechanistic and mechanistic population PK/PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004; 58(6): 618–31PubMedCrossRef Pillai G, Gieschke R, Goggin T, et al. A semimechanistic and mechanistic population PK/PD model for biomarker response to ibandronate, a new bisphosphonate for the treatment of osteoporosis. Br J Clin Pharmacol 2004; 58(6): 618–31PubMedCrossRef
36.
Zurück zum Zitat Tod M, Farcy-Afif M, Stocco J, et al. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet 2005; 44(4): 417–28PubMedCrossRef Tod M, Farcy-Afif M, Stocco J, et al. Pharmacokinetic/pharmacodynamic and time-to-event models of ribavirin-induced anaemia in chronic hepatitis C. Clin Pharmacokinet 2005; 44(4): 417–28PubMedCrossRef
37.
Zurück zum Zitat Gruwez B, Dauphin A, Tod M. A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. J Pharmacokinet Pharmacodyn 2005; 32(5–6): 663–83PubMedCrossRef Gruwez B, Dauphin A, Tod M. A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. J Pharmacokinet Pharmacodyn 2005; 32(5–6): 663–83PubMedCrossRef
38.
Zurück zum Zitat Gruwez B, Poirier MF, Dauphin A, et al. A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipraminelithium interaction. Contemp Clin Trials 2007; 28(3): 276–87PubMedCrossRef Gruwez B, Poirier MF, Dauphin A, et al. A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipraminelithium interaction. Contemp Clin Trials 2007; 28(3): 276–87PubMedCrossRef
39.
Zurück zum Zitat Hénin E, Zuideveld KP, Dartois C, et al. A KPD model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine [abstract no. 929; online]. Annual Meeting of the Population Approach Group in Europe; 2006 Jan 14–16; Bruges. Available from URL: http://www.page-meeting.org/?.abstract=929 [Accessed 2008 Feb 19] Hénin E, Zuideveld KP, Dartois C, et al. A KPD model for ordered categorical data: application to toxicity score in colorectal cancer patients treated with capecitabine [abstract no. 929; online]. Annual Meeting of the Population Approach Group in Europe; 2006 Jan 14–16; Bruges. Available from URL: http://​www.​page-meeting.​org/​?​.​abstract=​929 [Accessed 2008 Feb 19]
40.
Zurück zum Zitat Grass GM, Sinko PJ. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 2002; 54(3): 433–51PubMedCrossRef Grass GM, Sinko PJ. Physiologically-based pharmacokinetic simulation modelling. Adv Drug Deliv Rev 2002; 54(3): 433–51PubMedCrossRef
41.
Zurück zum Zitat Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001; 120(1–3): 411–20PubMedCrossRef Nestorov I. Modelling and simulation of variability and uncertainty in toxicokinetics and pharmacokinetics. Toxicol Lett 2001; 120(1–3): 411–20PubMedCrossRef
42.
Zurück zum Zitat Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33: 469–503PubMed Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33: 469–503PubMed
43.
Zurück zum Zitat Yang F, Tong X, McCarver DG, et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006; 33(4): 485–518PubMedCrossRef Yang F, Tong X, McCarver DG, et al. Population-based analysis of methadone distribution and metabolism using an age-dependent physiologically based pharmacokinetic model. J Pharmacokinet Pharmacodyn 2006; 33(4): 485–518PubMedCrossRef
44.
Zurück zum Zitat Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95(6): 1238–57PubMedCrossRef Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci 2006; 95(6): 1238–57PubMedCrossRef
45.
Zurück zum Zitat Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94(6): 1259–76PubMedCrossRef Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases. J Pharm Sci 2005; 94(6): 1259–76PubMedCrossRef
46.
Zurück zum Zitat Nestorov IA, Aarons LJ, Arundel PA, et al. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1998; 26(1): 21–46PubMedCrossRef Nestorov IA, Aarons LJ, Arundel PA, et al. Lumping of whole-body physiologically based pharmacokinetic models. J Pharmacokinet Biopharm 1998; 26(1): 21–46PubMedCrossRef
47.
Zurück zum Zitat Gueorguieva I, Nestorov IA, Rowland M. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study. J Pharmacokinet Pharmacodyn 2006; 33(1): 1–27PubMedCrossRef Gueorguieva I, Nestorov IA, Rowland M. Reducing whole body physiologically based pharmacokinetic models using global sensitivity analysis: diazepam case study. J Pharmacokinet Pharmacodyn 2006; 33(1): 1–27PubMedCrossRef
48.
Zurück zum Zitat Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006; 45(10): 1013–34PubMedCrossRef Edginton AN, Schmitt W, Willmann S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet 2006; 45(10): 1013–34PubMedCrossRef
49.
Zurück zum Zitat Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45(9): 931–56PubMedCrossRef Johnson TN, Rostami-Hodjegan A, Tucker GT. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children. Clin Pharmacokinet 2006; 45(9): 931–56PubMedCrossRef
50.
Zurück zum Zitat Wodarz D, Nowak MA. Mathematical models of HIV pathogenesis and treatment. Bioessays 2002; 24(12): 1178–87PubMedCrossRef Wodarz D, Nowak MA. Mathematical models of HIV pathogenesis and treatment. Bioessays 2002; 24(12): 1178–87PubMedCrossRef
51.
Zurück zum Zitat Duval V, Chabaud S, Girard P, et al. Physiologically based model of acute ischemic stroke. J Cereb Blood Flow Metab 2002; 22(8): 1010–8PubMedCrossRef Duval V, Chabaud S, Girard P, et al. Physiologically based model of acute ischemic stroke. J Cereb Blood Flow Metab 2002; 22(8): 1010–8PubMedCrossRef
52.
Zurück zum Zitat Chabaud S, Girard P, Nony P, et al. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002; 29(4): 339–63PubMedCrossRef Chabaud S, Girard P, Nony P, et al. Clinical trial simulation using therapeutic effect modeling: application to ivabradine efficacy in patients with angina pectoris. J Pharmacokinet Pharmacodyn 2002; 29(4): 339–63PubMedCrossRef
53.
Zurück zum Zitat Post TM, Freijer JI, DeJongh J, et al. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 2005; 22(7): 1038–49PubMedCrossRef Post TM, Freijer JI, DeJongh J, et al. Disease system analysis: basic disease progression models in degenerative disease. Pharm Res 2005; 22(7): 1038–49PubMedCrossRef
54.
Zurück zum Zitat Holford NH, Chan PL, Nutt JG, et al. Disease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006; 33(3): 281–311PubMedCrossRef Holford NH, Chan PL, Nutt JG, et al. Disease progression and pharmacodynamics in Parkinson disease: evidence for functional protection with levodopa and other treatments. J Pharmacokinet Pharmacodyn 2006; 33(3): 281–311PubMedCrossRef
55.
Zurück zum Zitat Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters: III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11(3): 303–19PubMedCrossRef Sheiner LB, Beal SL. Evaluation of methods for estimating population pharmacokinetic parameters: III. Monoexponential model: routine clinical pharmacokinetic data. J Pharmacokinet Biopharm 1983; 11(3): 303–19PubMedCrossRef
56.
Zurück zum Zitat Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 1991; 19(3): 333–53PubMedCrossRef Hashimoto Y, Sheiner LB. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis. J Pharmacokinet Biopharm 1991; 19(3): 333–53PubMedCrossRef
57.
Zurück zum Zitat Al Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 1990; 18: 347–60PubMedCrossRef Al Banna MK, Kelman AW, Whiting B. Experimental design and efficient parameter estimation in population pharmacokinetics. J Pharmacokinet Biopharm 1990; 18: 347–60PubMedCrossRef
58.
Zurück zum Zitat Ette EI, Howie CA, Kelman AW, et al. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Pharm Res 1995; 12(5): 729–37PubMedCrossRef Ette EI, Howie CA, Kelman AW, et al. Experimental design and efficient parameter estimation in preclinical pharmacokinetic studies. Pharm Res 1995; 12(5): 729–37PubMedCrossRef
59.
Zurück zum Zitat Aarons L, Balant LP, Mentré F, et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 1996; 49(4): 251–4PubMedCrossRef Aarons L, Balant LP, Mentré F, et al. Practical experience and issues in designing and performing population pharmacokinetic/pharmacodynamic studies. Eur J Clin Pharmacol 1996; 49(4): 251–4PubMedCrossRef
60.
Zurück zum Zitat Mallet A, Mentré F. An approach to the design of experiments for estimating the distribution of parameters in random models. In: Vichinevetsky R, Borne P, Vignes J, editors. 12th IMACS World Congress; 1988 Jul 18–22. Villeneuve d’Ascq: Gerfidn, 1988: 134-7 Mallet A, Mentré F. An approach to the design of experiments for estimating the distribution of parameters in random models. In: Vichinevetsky R, Borne P, Vignes J, editors. 12th IMACS World Congress; 1988 Jul 18–22. Villeneuve d’Ascq: Gerfidn, 1988: 134-7
61.
Zurück zum Zitat Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika 1997; 84: 429–42CrossRef Mentré F, Mallet A, Baccar D. Optimal design in random-effects regression models. Biometrika 1997; 84: 429–42CrossRef
62.
Zurück zum Zitat Merlé Y, Tod M. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design. J Pharmacokinet Biopharm 2001; 4: 365–90 Merlé Y, Tod M. Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design. J Pharmacokinet Biopharm 2001; 4: 365–90
63.
Zurück zum Zitat Retout S, Duffull S, Mentré F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 2001; 65(2): 141–51PubMedCrossRef Retout S, Duffull S, Mentré F. Development and implementation of the population Fisher information matrix for the evaluation of population pharmacokinetic designs. Comput Methods Programs Biomed 2001; 65(2): 141–51PubMedCrossRef
64.
Zurück zum Zitat Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixedeffects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat Med 2002; 21(18): 2623–39PubMedCrossRef Retout S, Mentré F, Bruno R. Fisher information matrix for non-linear mixedeffects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics. Stat Med 2002; 21(18): 2623–39PubMedCrossRef
65.
Zurück zum Zitat Duffull SB, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Comput Methods Programs Biomed 2002; 69(1): 25–35PubMedCrossRef Duffull SB, Retout S, Mentré F. The use of simulated annealing for finding optimal population designs. Comput Methods Programs Biomed 2002; 69(1): 25–35PubMedCrossRef
66.
Zurück zum Zitat Mentré F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn 2001; 28(3): 299–319PubMedCrossRef Mentré F, Dubruc C, Thenot JP. Population pharmacokinetic analysis and optimization of the experimental design for mizolastine solution in children. J Pharmacokinet Pharmacodyn 2001; 28(3): 299–319PubMedCrossRef
67.
Zurück zum Zitat Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res 2001; 18(1): 83–9PubMedCrossRef Duffull SB, Mentré F, Aarons L. Optimal design of a population pharmacodynamic experiment for ivabradine. Pharm Res 2001; 18(1): 83–9PubMedCrossRef
68.
Zurück zum Zitat Retout S, Mentré F. Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn 2003; 30(6): 417–43PubMedCrossRef Retout S, Mentré F. Optimization of individual and population designs using Splus. J Pharmacokinet Pharmacodyn 2003; 30(6): 417–43PubMedCrossRef
69.
Zurück zum Zitat Duffull S, Waterhouse T, Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2005; 32(3–4): 441–57PubMedCrossRef Duffull S, Waterhouse T, Eccleston J. Some considerations on the design of population pharmacokinetic studies. J Pharmacokinet Pharmacodyn 2005; 32(3–4): 441–57PubMedCrossRef
70.
Zurück zum Zitat Tod M, Mentré F, Merlé Y, et al. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. J Pharmacokinet Biopharm 1998; 26: 689–716PubMedCrossRef Tod M, Mentré F, Merlé Y, et al. Robust optimal design for the estimation of hyperparameters in population pharmacokinetics. J Pharmacokinet Biopharm 1998; 26: 689–716PubMedCrossRef
71.
Zurück zum Zitat Dodds MG, Hooker AC, Vicini P. Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn 2005; 32(1): 33–64PubMedCrossRef Dodds MG, Hooker AC, Vicini P. Robust population pharmacokinetic experiment design. J Pharmacokinet Pharmacodyn 2005; 32(1): 33–64PubMedCrossRef
72.
Zurück zum Zitat Foracchia M, Hooker A, Vicini P, et al. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 2004; 74(1): 29–46PubMedCrossRef Foracchia M, Hooker A, Vicini P, et al. POPED, a software for optimal experiment design in population kinetics. Comput Methods Programs Biomed 2004; 74(1): 29–46PubMedCrossRef
73.
Zurück zum Zitat Palmer JL, Muller P. Bayesian optimal design in population models for haematologic data. Stat Med 1998; 17(14): 1613–22PubMedCrossRef Palmer JL, Muller P. Bayesian optimal design in population models for haematologic data. Stat Med 1998; 17(14): 1613–22PubMedCrossRef
74.
Zurück zum Zitat Mentré F, Burtin P, Merlé Y, et al. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Inform J 1995; 29: 997–1019CrossRef Mentré F, Burtin P, Merlé Y, et al. Sparse-sampling optimal designs in pharmacokinetics and toxicokinetics. Drug Inform J 1995; 29: 997–1019CrossRef
75.
Zurück zum Zitat Hooker A, Vicini P. Simultaneous population optimal design for pharmacokineticpharmacodynamic experiments. AAPS J 2005 Nov 1; 7(4): E759–85PubMedCrossRef Hooker A, Vicini P. Simultaneous population optimal design for pharmacokineticpharmacodynamic experiments. AAPS J 2005 Nov 1; 7(4): E759–85PubMedCrossRef
76.
Zurück zum Zitat Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. J Pharmacokin Biopharm 1992; 20: 279–94CrossRef Wang J, Endrenyi L. A computationally efficient approach for the design of population pharmacokinetic studies. J Pharmacokin Biopharm 1992; 20: 279–94CrossRef
77.
Zurück zum Zitat Kowalski KG, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 2001; 20(1): 75–91PubMedCrossRef Kowalski KG, Hutmacher MM. Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study. Stat Med 2001; 20(1): 75–91PubMedCrossRef
78.
Zurück zum Zitat Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33(5): 469–503PubMed Price PS, Conolly RB, Chaisson CF, et al. Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol 2003; 33(5): 469–503PubMed
79.
Zurück zum Zitat Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 2004; 93(10): 2522–34PubMedCrossRef Nagilla R, Ward KW. A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog, and monkey to humans. J Pharm Sci 2004; 93(10): 2522–34PubMedCrossRef
80.
Zurück zum Zitat West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284(5420): 1677–9PubMedCrossRef West GB, Brown JH, Enquist BJ. The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science 1999; 284(5420): 1677–9PubMedCrossRef
81.
Zurück zum Zitat West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276(5309): 122–6PubMedCrossRef West GB, Brown JH, Enquist BJ. A general model for the origin of allometric scaling laws in biology. Science 1997; 276(5309): 122–6PubMedCrossRef
82.
Zurück zum Zitat Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63(1): 75–84PubMedCrossRef Anderson BJ, Allegaert K, Van den Anker JN, et al. Vancomycin pharmacokinetics in preterm neonates and the prediction of adult clearance. Br J Clin Pharmacol 2007; 63(1): 75–84PubMedCrossRef
83.
Zurück zum Zitat Tod M, Lokiec F, Bidault R, et al. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother 2001; 45(1): 150–7PubMedCrossRef Tod M, Lokiec F, Bidault R, et al. Pharmacokinetics of oral acyclovir in neonates and in infants: a population analysis. Antimicrob Agents Chemother 2001; 45(1): 150–7PubMedCrossRef
84.
Zurück zum Zitat De Bony F, Tod M, Bidault R, et al. Multiple interactions of Cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother 2002; 46(2): 458–63PubMedCrossRef De Bony F, Tod M, Bidault R, et al. Multiple interactions of Cimetidine and probenecid with valaciclovir and its metabolite acyclovir. Antimicrob Agents Chemother 2002; 46(2): 458–63PubMedCrossRef
85.
Zurück zum Zitat Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci 2000; 2(1): E3PubMed Hayton WL. Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci 2000; 2(1): E3PubMed
86.
Zurück zum Zitat Hale M, Gillespie WR, Gupta SK, et al. Clinical trials simulation: streamlining your drug development process. Appl Clin Trial 1996; 5: 35–40 Hale M, Gillespie WR, Gupta SK, et al. Clinical trials simulation: streamlining your drug development process. Appl Clin Trial 1996; 5: 35–40
87.
Zurück zum Zitat Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992; 81(6): 605–10PubMedCrossRef Peck CC, Barr WH, Benet LZ, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. J Pharm Sci 1992; 81(6): 605–10PubMedCrossRef
88.
Zurück zum Zitat Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40: 209–34PubMedCrossRef Holford NH, Kimko HC, Monteleone JP, et al. Simulation of clinical trials. Annu Rev Pharmacol Toxicol 2000; 40: 209–34PubMedCrossRef
89.
Zurück zum Zitat European Center of Pharmaceutical Medicine/Center for Drug Development Science. Frontiers in Drug Development: Computer Simulation and Modelling; 1996 Oct 18; Basel European Center of Pharmaceutical Medicine/Center for Drug Development Science. Frontiers in Drug Development: Computer Simulation and Modelling; 1996 Oct 18; Basel
90.
Zurück zum Zitat Center for Drug Development Science. Modeling and Simulation of Clinical Trials in Drug Development and Regulation; 1997 Nov; Reston (VA) Center for Drug Development Science. Modeling and Simulation of Clinical Trials in Drug Development and Regulation; 1997 Nov; Reston (VA)
92.
93.
Zurück zum Zitat Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997; 35(10): 469–74PubMed Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther 1997; 35(10): 469–74PubMed
94.
Zurück zum Zitat Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 2005; 96(3): 228–34PubMedCrossRef Girard P. Clinical trial simulation: a tool for understanding study failures and preventing them. Basic Clin Pharmacol Toxicol 2005; 96(3): 228–34PubMedCrossRef
95.
Zurück zum Zitat Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996; 24(3): 265–82PubMedCrossRef Girard P, Sheiner LB, Kastrissios H, et al. Do we need full compliance data for population pharmacokinetic analysis? J Pharmacokinet Biopharm 1996; 24(3): 265–82PubMedCrossRef
96.
Zurück zum Zitat Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998; 17(20): 2313–33PubMedCrossRef Girard P, Blaschke TF, Kastrissios H, et al. A Markov mixed effect regression model for drug compliance. Stat Med 1998; 17(20): 2313–33PubMedCrossRef
97.
Zurück zum Zitat Wong D, Modi R, Ramanathan M. Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Pharmacokinet 2003; 42(2): 193–204PubMedCrossRef Wong D, Modi R, Ramanathan M. Assessment of Markov-dependent stochastic models for drug administration compliance. Clin Pharmacokinet 2003; 42(2): 193–204PubMedCrossRef
98.
Zurück zum Zitat Labbe L, Verotta D. A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J Pharmacokinet Pharmacodyn 2006; 33(4): 519–42PubMedCrossRef Labbe L, Verotta D. A non-linear mixed effect dynamic model incorporating prior exposure and adherence to treatment to describe long-term therapy outcome in HIV-patients. J Pharmacokinet Pharmacodyn 2006; 33(4): 519–42PubMedCrossRef
99.
Zurück zum Zitat Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003; 30(1): 83–103PubMedCrossRef Hu C, Sale ME. A joint model for nonlinear longitudinal data with informative dropout. J Pharmacokinet Pharmacodyn 2003; 30(1): 83–103PubMedCrossRef
100.
Zurück zum Zitat Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64(6): 672–83PubMedCrossRef Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 1998; 64(6): 672–83PubMedCrossRef
101.
Zurück zum Zitat Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60(6): 619–35PubMedCrossRef Mandema JW, Stanski DR. Population pharmacodynamic model for ketorolac analgesia. Clin Pharmacol Ther 1996; 60(6): 619–35PubMedCrossRef
102.
Zurück zum Zitat Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68(6): 677–87PubMedCrossRef Veyrat-Follet C, Bruno R, Olivares R, et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization. Clin Pharmacol Ther 2000; 68(6): 677–87PubMedCrossRef
103.
Zurück zum Zitat Nestorov I, Graham G, Duffull S, et al. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res 2001; 18(8): 1210–9PubMedCrossRef Nestorov I, Graham G, Duffull S, et al. Modeling and stimulation for clinical trial design involving a categorical response: a phase II case study with naratriptan. Pharm Res 2001; 18(8): 1210–9PubMedCrossRef
104.
Zurück zum Zitat Jumbe N, Yao B, Rovetti R, et al. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology (Huntingt) 2002; 16 (10 Suppl.11): 37–44 Jumbe N, Yao B, Rovetti R, et al. Clinical trial simulation of a 200-microg fixed dose of darbepoetin alfa in chemotherapy-induced anemia. Oncology (Huntingt) 2002; 16 (10 Suppl.11): 37–44
105.
Zurück zum Zitat Lockwood P, Ewy W, Hermann D, et al. Application of a clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer’s disease. Pharm Res 2006; 23: 2050–9PubMedCrossRef Lockwood P, Ewy W, Hermann D, et al. Application of a clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer’s disease. Pharm Res 2006; 23: 2050–9PubMedCrossRef
106.
Zurück zum Zitat Kimko HC, Reele SS, Holford NH, et al. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000; 68(5): 568–77PubMedCrossRef Kimko HC, Reele SS, Holford NH, et al. Prediction of the outcome of a phase 3 clinical trial of an antischizophrenic agent (quetiapine fumarate) by simulation with a population pharmacokinetic and pharmacodynamic model. Clin Pharmacol Ther 2000; 68(5): 568–77PubMedCrossRef
107.
Zurück zum Zitat Krishna R, Krishnaswami S, Kittner B, et al. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004; 25(9): 373–87PubMedCrossRef Krishna R, Krishnaswami S, Kittner B, et al. The utility of mixed-effects covariate analysis in rapid selection of doses in pediatric subjects: a case study with fexofenadine hydrochloride. Biopharm Drug Dispos 2004; 25(9): 373–87PubMedCrossRef
108.
Zurück zum Zitat Yim DS, Zhou H, Buckwalter M, et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005; 45(3): 246–56PubMedCrossRef Yim DS, Zhou H, Buckwalter M, et al. Population pharmacokinetic analysis and simulation of the time-concentration profile of etanercept in pediatric patients with juvenile rheumatoid arthritis. J Clin Pharmacol 2005; 45(3): 246–56PubMedCrossRef
109.
Zurück zum Zitat Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK/PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 2007; 29(4): 239–47PubMedCrossRef Avramis VI, Spence SA. Clinical pharmacology of asparaginases in the United States: asparaginase population pharmacokinetic and pharmacodynamic (PK/PD) models (NONMEM) in adult and pediatric ALL patients. J Pediatr Hematol Oncol 2007; 29(4): 239–47PubMedCrossRef
110.
Zurück zum Zitat Ramakrishnan R, Migoya E, Knorr B. A population pharmacokinetic model for montelukast disposition in adults and children. Pharm Res 2005; 22(4): 532–40PubMedCrossRef Ramakrishnan R, Migoya E, Knorr B. A population pharmacokinetic model for montelukast disposition in adults and children. Pharm Res 2005; 22(4): 532–40PubMedCrossRef
111.
Zurück zum Zitat Blumer JL, Reed MD, Kaplan EL, et al. Explaining the poor bacteriologie eradication rate of single-dose ceftriaxone in group A streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling. Pediatrics 2005; 116(4): 927–32PubMedCrossRef Blumer JL, Reed MD, Kaplan EL, et al. Explaining the poor bacteriologie eradication rate of single-dose ceftriaxone in group A streptococcal tonsillopharyngitis: a reverse engineering solution using pharmacodynamic modeling. Pediatrics 2005; 116(4): 927–32PubMedCrossRef
Metadaten
Titel
Facilitation of Drug Evaluation in Children by Population Methods and Modelling
verfasst von
Dr Michel Tod
Vincent Jullien
Gérard Pons
Publikationsdatum
01.04.2008
Verlag
Springer International Publishing
Erschienen in
Clinical Pharmacokinetics / Ausgabe 4/2008
Print ISSN: 0312-5963
Elektronische ISSN: 1179-1926
DOI
https://doi.org/10.2165/00003088-200847040-00002

Weitere Artikel der Ausgabe 4/2008

Clinical Pharmacokinetics 4/2008 Zur Ausgabe